UY36671A - COMPOSICIONES DE ARNi CONTRA Factor XII (FACTOR DE Hageman) (F12),CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMO - Google Patents

COMPOSICIONES DE ARNi CONTRA Factor XII (FACTOR DE Hageman) (F12),CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMO

Info

Publication number
UY36671A
UY36671A UY0001036671A UY36671A UY36671A UY 36671 A UY36671 A UY 36671A UY 0001036671 A UY0001036671 A UY 0001036671A UY 36671 A UY36671 A UY 36671A UY 36671 A UY36671 A UY 36671A
Authority
UY
Uruguay
Prior art keywords
factor
gene
kng1
methods
plasmatic
Prior art date
Application number
UY0001036671A
Other languages
English (en)
Spanish (es)
Inventor
Maier Martin
Hinkle Gregory
Akinc Akin
Liu Jingxuan
Butler James
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Priority to UY0001040330A priority Critical patent/UY40330A/es
Publication of UY36671A publication Critical patent/UY36671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001036671A 2015-05-06 2016-05-06 COMPOSICIONES DE ARNi CONTRA Factor XII (FACTOR DE Hageman) (F12),CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMO UY36671A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY0001040330A UY40330A (es) 2015-05-06 2016-05-06 COMPOSICIONES DE ARNi CONTRA FACTOR XII (FACTOR DE HAGEMAN) (F12) Y MÉTODOS DE USO DE LOS MISMOS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157890P 2015-05-06 2015-05-06
US201562260887P 2015-11-30 2015-11-30
US201562266958P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
UY36671A true UY36671A (es) 2016-12-30

Family

ID=55971215

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001036671A UY36671A (es) 2015-05-06 2016-05-06 COMPOSICIONES DE ARNi CONTRA Factor XII (FACTOR DE Hageman) (F12),CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMO
UY0001040330A UY40330A (es) 2015-05-06 2016-05-06 COMPOSICIONES DE ARNi CONTRA FACTOR XII (FACTOR DE HAGEMAN) (F12) Y MÉTODOS DE USO DE LOS MISMOS

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001040330A UY40330A (es) 2015-05-06 2016-05-06 COMPOSICIONES DE ARNi CONTRA FACTOR XII (FACTOR DE HAGEMAN) (F12) Y MÉTODOS DE USO DE LOS MISMOS

Country Status (13)

Country Link
US (4) US20180100150A1 (cg-RX-API-DMAC7.html)
EP (1) EP3292201A2 (cg-RX-API-DMAC7.html)
JP (4) JP6695902B2 (cg-RX-API-DMAC7.html)
KR (2) KR102827366B1 (cg-RX-API-DMAC7.html)
CN (2) CN108271386B (cg-RX-API-DMAC7.html)
AU (3) AU2016257996A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017021967A2 (cg-RX-API-DMAC7.html)
CA (1) CA2984636A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792444A1 (cg-RX-API-DMAC7.html)
HK (1) HK1249920A1 (cg-RX-API-DMAC7.html)
TW (4) TW202536180A (cg-RX-API-DMAC7.html)
UY (2) UY36671A (cg-RX-API-DMAC7.html)
WO (1) WO2016179342A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016233364A1 (en) * 2015-03-17 2017-09-21 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of factor Xll
WO2016179342A2 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
WO2017120397A1 (en) * 2016-01-08 2017-07-13 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting factor xii (hageman factor) (f12) and methods of use thereof
CN119548520A (zh) * 2017-01-30 2025-03-04 箭头药业股份有限公司 用于抑制因子xii基因表达的组合物和方法
NZ757927A (en) 2017-04-11 2023-07-28 Arbutus Biopharma Corp Targeted compositions
US20200208150A1 (en) * 2017-07-07 2020-07-02 Alnylam Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
JP7727308B2 (ja) 2017-12-01 2025-08-21 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
JP7365052B2 (ja) 2017-12-01 2023-10-19 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
JP7273417B2 (ja) 2017-12-01 2023-05-15 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
DK3732185T3 (da) 2017-12-29 2025-03-31 Suzhou Ribo Life Science Co Ltd Konjugater og fremstilling og anvendelse heraf
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
CN111655297A (zh) 2018-09-30 2020-09-11 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
EP3903830A4 (en) 2018-12-28 2023-04-26 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
CN113330117B (zh) * 2019-01-18 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US20240200060A1 (en) * 2019-05-22 2024-06-20 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP7614650B2 (ja) * 2019-05-24 2025-01-16 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体並びに調製方法と使用
CA3169813A1 (en) * 2020-02-07 2021-08-12 Intellia Therapeutics, Inc. Compositions and methods for kallikrein ( klkb1) gene editing
WO2021195574A1 (en) * 2020-03-27 2021-09-30 Alnylam Pharmaceuticals, Inc. Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AR124408A1 (es) 2020-12-18 2023-03-22 Ionis Pharmaceuticals Inc Compuestos y métodos para modular el factor xii
JP2024534766A (ja) 2021-08-13 2024-09-26 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
TW202346586A (zh) * 2022-01-28 2023-12-01 大陸商上海舶望製藥有限公司 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法
WO2024169577A1 (zh) * 2023-02-14 2024-08-22 北京福元医药股份有限公司 用于抑制fxii基因表达的双链核糖核酸及其修饰物、缀合物和用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1861608A (en) 1929-12-21 1932-06-07 Emerson Electric Mfg Co Fan and means for directing the air current therethrough
US1861108A (en) 1930-01-24 1932-05-31 Eugene O Brace Integral clutch and transmission control
US3974808A (en) 1975-07-02 1976-08-17 Ford Motor Company Air intake duct assembly
US4708708A (en) 1982-12-06 1987-11-24 International Paper Company Method and apparatus for skiving and hemming
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
NL8901881A (nl) 1989-07-20 1991-02-18 Rockwool Grodan Bv Drainagekoppelelement.
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
RU2123492C1 (ru) 1993-02-19 1998-12-20 Ниппон Синяку Ко., Лтд Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6034135A (en) 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EP1042280A2 (en) 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
ATE237312T1 (de) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
BR9914773A (pt) 1998-10-09 2002-02-05 Ingene Inc Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
IL142490A0 (en) 1998-10-09 2002-03-10 Ingene Inc ENZYMATIC SYNTHESIS OF ssDNA
TWI260322B (en) 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
EP2070939B1 (en) * 2001-05-25 2014-04-02 Duke University Modulators of pharmacological agents
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
CN101133074B (zh) * 2004-09-24 2012-05-30 阿尔尼拉姆医药品有限公司 APOB的RNAi调节及其用途
CA2630838A1 (en) * 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CA2658183A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
US20110154517A1 (en) * 2007-10-22 2011-06-23 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
PE20120115A1 (es) * 2008-11-17 2012-02-20 Hoffmann La Roche Composiciones y metodos para inhibir la expresion de genes del factor vii
PL2440183T3 (pl) 2009-06-10 2019-01-31 Arbutus Biopharma Corporation Ulepszona formulacja lipidowa
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9512164B2 (en) 2009-07-07 2016-12-06 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2012064758A2 (en) * 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CA2839573A1 (en) * 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
IL303831A (en) * 2011-11-18 2023-08-01 Alnylam Pharmaceuticals Inc Adapted RNAI factors
CN102600471A (zh) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 一种败血症治疗的靶点
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
MY177989A (en) 2013-01-30 2020-09-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates
SMT201700552T1 (it) * 2013-03-14 2018-01-11 Alnylam Pharmaceuticals Inc COMPOSIZIONI DI iRNA DEL COMPONENTE DEL COMPLEMENTO C5 E LORO METODI DI USO
TWI664187B (zh) * 2013-05-22 2019-07-01 阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
AP2015008862A0 (en) * 2013-05-22 2015-11-30 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
AU2016233364A1 (en) 2015-03-17 2017-09-21 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of factor Xll
WO2016149020A1 (en) 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
WO2016179342A2 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
WO2017120397A1 (en) * 2016-01-08 2017-07-13 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting factor xii (hageman factor) (f12) and methods of use thereof
EP3544617A4 (en) 2016-11-23 2020-08-05 Alnylam Pharmaceuticals, Inc. REDUCED OFF-TARGET MODIFIED RNA AGENTS
CN119548520A (zh) 2017-01-30 2025-03-04 箭头药业股份有限公司 用于抑制因子xii基因表达的组合物和方法
US20200208150A1 (en) 2017-07-07 2020-07-02 Alnylam Pharmaceuticals, Inc. METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
JP2024534766A (ja) 2021-08-13 2024-09-26 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法

Also Published As

Publication number Publication date
BR112017021967A2 (pt) 2018-07-31
US20240076664A1 (en) 2024-03-07
AU2024200717B2 (en) 2025-12-18
TW201704472A (zh) 2017-02-01
TW202130811A (zh) 2021-08-16
TWI727948B (zh) 2021-05-21
KR102827366B1 (ko) 2025-07-03
HK1249920A1 (zh) 2018-11-16
CA2984636A1 (en) 2016-11-10
US20180100150A1 (en) 2018-04-12
US12338439B2 (en) 2025-06-24
WO2016179342A3 (en) 2017-01-12
UY40330A (es) 2023-08-15
JP6695902B2 (ja) 2020-05-20
TWI806034B (zh) 2023-06-21
KR20180002688A (ko) 2018-01-08
WO2016179342A2 (en) 2016-11-10
TWI887656B (zh) 2025-06-21
TW202536180A (zh) 2025-09-16
AU2016257996A1 (en) 2017-10-26
CN108271386A (zh) 2018-07-10
JP7530204B2 (ja) 2024-08-07
AU2024200717A1 (en) 2024-04-18
CN115322991A (zh) 2022-11-11
JP2022141707A (ja) 2022-09-29
AU2021258003A1 (en) 2021-11-25
EA201792444A1 (ru) 2018-06-29
US20200131513A1 (en) 2020-04-30
TW202336231A (zh) 2023-09-16
EP3292201A2 (en) 2018-03-14
KR20250107273A (ko) 2025-07-11
US20210246447A1 (en) 2021-08-12
US10934544B2 (en) 2021-03-02
CN108271386B (zh) 2022-07-15
JP2024037849A (ja) 2024-03-19
JP2020188756A (ja) 2020-11-26
WO2016179342A9 (en) 2016-12-08
JP2018519797A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
UY36671A (es) COMPOSICIONES DE ARNi CONTRA Factor XII (FACTOR DE Hageman) (F12),CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMO
CL2021002998A1 (es) Composiciones de arni contra tmprss6 y métodos para su uso (divisional de solicitud n° 03440-2015)
CL2019000107A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014)
AR121312A2 (es) AGENTES DE ARNi, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
CL2023002870A1 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso
MX2025007610A (es) Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas
UY35582A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
CL2018000198A1 (es) Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr
MX382900B (es) COMPOSICIONES DE ÁCIDO RIBONUCLEICO DE INTERFERENCIA (ARNi) CONTRA EL COMPONENTE DEL COMPLEMENTO Y MÉTODOS PARA SU USO.
UY37494A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
AR102777A1 (es) COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CO2022009787A2 (es) Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
CO2024006046A2 (es) Composiciones de arni contra el factor b del complemento (cfb) y sus métodos de uso
MX2020003554A (es) Moduladores de la expresion de enac.
AR104542A1 (es) COMPOSICIONES DE ARNi CONTRA FACTOR XII (FACTOR DE HAGEMAN) (F12), CALICREÍNA B, PLASMÁTICA (FACTOR DE FLETCHER) 1 (KLKB1), Y QUININÓGENO 1 (KNG1) Y MÉTODOS DE USO DE LOS MISMOS
AR120712A1 (es) AGENTES DE ARNi DEL MARCO DE LECTURA ABIERTO 72 DEL CROMOSOMA 9 HUMANO (C9ORF72), COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS
AR116531A1 (es) COMPOSICIONES DE ARNi CONTRA EL GEN DE LA TRANSTIRETINA Y MÉTODOS DE TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES OCULARES ASOCIADAS A LA TTR CON DICHAS COMPOSICIONES
CL2017002646A1 (es) Composiciones de arni de serpina1 y sus métodos de uso (divisional de solicitud n° 3441-2015).
CR20150644A (es) Composiciones de arni de serapina 1 y sus métodos de uso
BR112018009311A8 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
AR095329A1 (es) COMPOSICIONES DE ÁCIDO RIBONUCLEICO INTERFERENTE (ARNi) DEL COMPONENTE DEL COMPLEMENTO C5 Y MÉTODOS PARA SU USO

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20240423